Evidence map›Paper›PMID 42893198›Full record

ArticleBlood neoplasia2026

Pitavastatin counteracts venetoclax resistance mechanisms including

Roberta Buono, Dennis Juarez, Madhuri Paul, Sarah J Skuli, Ian B Wong, Ishita Tarnekar, Zhili Ying, Izabelle Marie F Le, Wen-Pin Chen, Min Zhang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Roberta BuonoDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Dennis JuarezDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Madhuri PaulDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Sarah J SkuliDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Ian B WongDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Ishita TarnekarDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Zhili YingDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Izabelle Marie F LeDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, University of California Irvine, Irvine, CA.
Wen-Pin ChenBiostatistics Shared Resource, University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA.
Min ZhangBiostatistics Shared Resource, University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA.
Gerald WertheimDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
A'ishah BakayokoDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Marisa KruidenierDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Dequina A NicholasDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.
Pankaj GuptaHematology/Oncology Section, VA Long Beach Healthcare System, Long Beach, CA.
Said M SebtiDepartment of Pharmacology and Toxicology and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA.
Marina KonoplevaAlbert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Angela G FleischmanDivision of Hematology-Oncology, Department of Medicine, University of California Irvine, Irvine, CA.
Cholsoon JangDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, University of California Irvine, Irvine, CA.
Martin CarrollDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
David A FrumanDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA.

Funding

CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
University of Pennsylvania Patient-derived Xenograft Development and Trials CenterU54CA283759 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MARTIN CARROLL · 2023 to 2026
$5.1M
Elucidating dietary fructose and alcohol interactions during liver cancer developmentR01AA029124 · NIAAA · UNIVERSITY OF CALIFORNIA-IRVINE · PI JANG, CHOLSOON · 2021 to 2025
$2.0M
NCI NIH HHS T32 CA009054NCI NIH HHS U54 CA283759NIAAA NIH HHS R01 AA029124
6 · The paper itself

Abstract

The B-cell lymphoma 2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in

Identifiers

PMID42893198
PMCPMC13676112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.